PCN43 Cost-Effectiveness of Nivolumab for the Treatment of Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy: A United-States Payer Perspective
Abstract
Authors
I. Orsini J. Gricar D. Bertwistle I. Kim M. Kurt